News and Trends 3 Oct 2022 Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA vaccine projects at the University of British Columbia (UBC). The funding, through the Pacific Economic Development Agency of Canada (PacifiCan), is for UBC to enhance the delivery and efficacy of mRNA vaccines. PacifiCan is investing the money through its Regional […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 PharmAla Biotech files patent applications for MDMA analogs Canadian company PharmAla Biotech has filed a key patent cooperation treaty (PCT) application, containing six novel chemical entities (NCEs). The application claims priority to, and benefit of a United States provisional patent application filed August 20, 2021. The PCT application disclosed novel compositions of MDMA and analogs that may be used to alleviate the known […] August 29, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2022 Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean Tetra Bio-Pharma Inc., a company working in cannabinoid-based drug discovery and development, has announced it has entered into a subscription agreement with investment vehicle Global Corporate Finance Opportunities 16 (GCFO 16). The announcement came yesterday (August 11) after Alpha Blue Ocean (ABO) advised the partnership whereby Canadian-based Tetra agrees to issue investor GCFO 16 senior […] August 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Epilepsy drug accepted for review in Canada and Israel SK Biopharmaceuticals, Co., Ltd. says Health Canada has accepted Paladin Labs Inc.’s filing of a new drug submission (NDS) for cenobamate as an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy. If Health Canada approves the NDS, Paladin Labs would be able to […] August 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery AbCellera and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ track record in forming innovative biotech companies, and AbCellera’s ability to quickly deliver lead drug candidates to bring transformational new medicines […] August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Defence Therapeutics says AccuTOX kills cancer cells Defence Therapeutics Inc., a Canadian biopharma company specializing in immune-oncology vaccines and drug delivery technologies, says it has discovered a novel DNA damaging function triggered by one of its lead compounds AccuTOX, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2022 The biggest US biotech investments in July 2022 The asthma specialist Areteia Therapeutics took the U.S.’ top private biotech investment crown in July 2022, with runners-up including liquid biopsy firm Delfi Diagnostics and the metabolic disease drug developer Carmot Therapeutics. The U.S.’ top private biotech investments in July 2022 didn’t reach the giddy heights of National Resilience’s $625 million Series D round in […] August 1, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2022 Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […] July 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Telo Genomics launches clinical study of drug resistance test for multiple myeloma Canadian biotech company Telo Genomics Corp. has started the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma (MM) patients at high-risk of developing treatment resistance. The study is the second being carried out in collaboration with the Mayo Clinic to evaluate the company’s prognostic technology to address multiple unmet clinical […] July 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for […] July 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2022 Chimerix awarded $25.3M Public Health Agency of Canada deal for smallpox drug Biopharma firm Chimerix has announced the Public Health Agency of Canada has awarded the company a contract of up to C$25.3 million (US$32.6 million) to procure TEMBEXA (brincidofovir). Execution of the contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent […] June 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email